Could a PARP inhibitor slow prostate cancer recurrence?

NCT ID NCT03047135

Ongoing Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the drug olaparib in 51 men whose prostate cancer has returned after surgery and is at high risk of spreading. Olaparib works by blocking a repair process that cancer cells rely on, especially those with certain DNA faults. The main goal is to see if the drug can lower PSA levels by at least half, which would suggest it is controlling the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE

Contacts and locations

Show contact details

Locations

Allegheny Cancer Center

Pittsburgh, Pennsylvania, 15212, United States
Johns Hopkins Hospital

Baltimore, Maryland, 21231, United States
Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States